Ithaka US Growth Strategy LLY
Bull thesis on Eli Lilly and Company from Ithaka US Growth Strategy
RiverPark Large Growth LLY
Bull thesis on Eli Lilly and Co. from RiverPark Large Growth
Alger Spectra Fund LLY
Bull thesis on Eli Lilly and Company from Alger Spectra Fund
Eli Lilly and Company
Pitch Summary: Eli Lilly and Company has demonstrated strong commercial execution and high R&D success rates, positioning it well for continued growth. The company is a global leader in diabetes with its drug tirzepatide, marketed under the Mounjaro and Zepbound brands, achieving record sales. With no significant patent expirations expected for the rest of the […]
Eli Lilly and Company
Pitch Summary: Eli Lilly has experienced significant growth, reaching a $1 trillion market cap, largely driven by its weight-loss injectables, Zepbound and Mounjaro. However, recent developments suggest that this growth may not be sustainable. The company’s valuation appears overstretched, and it faces significant competition from Novo Nordisk, which is aggressively pricing its oral weight-loss treatments. […]
Eli Lilly and Company
Pitch Summary: Eli Lilly is well-positioned for high growth due to its robust GLP-1 market share gains and significant sales growth of its Mounjaro and Zepbound products. Despite competition from oral obesity/diabetes therapies, the company’s strong performance and raised FY2025 guidance support a bullish outlook. BSD Analysis: Eli Lilly has demonstrated strong financial performance with […]
